Nirav Bhatt is an LLM candidate at Osgoode Hall Law School.

The much deliberated topic of making education easily accessible and available for no cost is indeed coming closer to reality, with a huge increase in the number of students using OpenCourseWare. With institutions like Harvard, Stanford, Oxford, Cambridge, and M.I.T making learning materials easily accessible online, there is a great opportunity for students to reap the benefits of the world of online education.

Read the rest of this entry »

Posted in Innovation, Internet
Comments: 0

Nirav Bhatt is an LLM candidate at Osgoode Hall Law School.

China’s economic progress is coming in leaps and bounds, be it rapid development of infrastructure or moving at a rate much faster than its counterparts. But the recent Google-China controversy raises concerns about whether this will cause major problems for China in the long run. In what is being witnessed as a strong political move, China had asked Google to comply with its national policies of internet censorship or abandon the country.

Read the rest of this entry »

Posted in Internet
Comments 3

Nirav Bhatt is an LLM candidate at Osgoode Hall Law School.

On Thursday, March 4, IP Osgoode hosted a talk by Frances Seghers, Executive Vice President, Worldwide Government Affairs for Sony Pictures Entertainment.  Her talk was a guest lecture in Barry Sookman’s intellectual property law class. Frances began the lecture by explaining a little bit about the work that she does and then moved on to a discussion of international copyright.

Read the rest of this entry »

Posted in copyright reform, events, IP
Comments: 0

Nirav Bhatt is an LLM candidate at Osgoode Hall Law School.

WTO members on 2 March 2010, debated the question of whether a 2003 decision designed to improve access to medicines is working. Although opinions expressed in the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Council varied, members agreed that they should look at real-life experiences in order to assess the system.

Read the rest of this entry »

Posted in IP, Patents, Pharmaceutical Drugs
Comments: 0